BR0013171A - Agentes multimericos para formação de imagem de objetivação através de ligação multi-local - Google Patents

Agentes multimericos para formação de imagem de objetivação através de ligação multi-local

Info

Publication number
BR0013171A
BR0013171A BR0013171-7A BR0013171A BR0013171A BR 0013171 A BR0013171 A BR 0013171A BR 0013171 A BR0013171 A BR 0013171A BR 0013171 A BR0013171 A BR 0013171A
Authority
BR
Brazil
Prior art keywords
compounds
scaffolding
halves
relates
present
Prior art date
Application number
BR0013171-7A
Other languages
English (en)
Inventor
Randall B Lauffer
Thomas J Mcmurry
Stephane Dumas
Andrew Kolodziej
John Amedio
Peter Caravan
Zhaoda Zhang
Shrikumar Nair
Original Assignee
Epix Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Medical Inc filed Critical Epix Medical Inc
Publication of BR0013171A publication Critical patent/BR0013171A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"AGENTES MULTIMERICOS PARA FORMAçãO DE IMAGEM DE OBJETIVAçãO ATRAVéS DE LIGAçãO MULTI-LOCAL". A presente invenção se A presente invenção se refere a agente de contraste para a formação de imagem diagnóstica. Em particular, a presente invenção se refere a novos compostos multiméricos os quais exibem afinidade aperfeiçoada por alvos fisiologicamente relevantes tais como proteínas e propriedades de relaxatividade surpreendentemente aperfeiçoadas quando de ligação. Os compostos compreende: a) duas ou mais Metades de Intensificação de Imagem ( IEMS ) ( ou metade de geração de sinal ) compreendendo subunidades múltiplas; b) duas ou mais Metades de Ligação ao Alvo ( TBM ), proporcionando a localização e rigidificação de multímero in vivo; c) uma rede de andaimes para fixação das metades acima ( "andaimes" ); e d) ligantes opcionais para fixação das IEMs ao andaime ( "ligante" ). A presente invenção também se refere a composições farmacêuticas compreendendo esses compostos e a métodos de uso de compostos e composições para intensificação de contraste durante a formação de imagem.
BR0013171-7A 1999-07-29 2000-07-28 Agentes multimericos para formação de imagem de objetivação através de ligação multi-local BR0013171A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14641499P 1999-07-29 1999-07-29
US16365099P 1999-11-04 1999-11-04
PCT/US2000/020536 WO2001008712A2 (en) 1999-07-29 2000-07-28 Targeting multimeric imaging agents through multilocus binding

Publications (1)

Publication Number Publication Date
BR0013171A true BR0013171A (pt) 2002-05-28

Family

ID=26843871

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013171-7A BR0013171A (pt) 1999-07-29 2000-07-28 Agentes multimericos para formação de imagem de objetivação através de ligação multi-local

Country Status (20)

Country Link
US (2) US6652835B1 (pt)
EP (1) EP1210124A2 (pt)
JP (2) JP2003505519A (pt)
KR (1) KR20020057946A (pt)
CN (2) CN1626246A (pt)
AU (1) AU6386000A (pt)
BR (1) BR0013171A (pt)
CA (1) CA2384565A1 (pt)
CZ (1) CZ2002343A3 (pt)
EA (1) EA200200220A1 (pt)
HK (1) HK1048952A1 (pt)
HU (1) HUP0202635A3 (pt)
IL (1) IL147854A0 (pt)
IS (1) IS6241A (pt)
MX (1) MXPA02001017A (pt)
NO (1) NO20020474L (pt)
NZ (1) NZ517017A (pt)
PL (1) PL353336A1 (pt)
WO (1) WO2001008712A2 (pt)
YU (1) YU6502A (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW319763B (pt) 1995-02-01 1997-11-11 Epix Medical Inc
US6713045B1 (en) 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
AU752812B2 (en) 1997-11-17 2002-10-03 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
HUP0202635A3 (en) * 1999-07-29 2006-03-28 Epix Medical Inc Cambridge Targeting multimeric imaging agents through multilocus binding
TWI290146B (en) * 1999-07-29 2007-11-21 Dyax Corp Binding moieties for fibrin
US6673333B1 (en) 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
AU2001276956A1 (en) 2000-07-17 2002-01-30 California Institute Of Technology Macrocyclic mri contrast agents
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
EP1443953A4 (en) * 2001-10-16 2005-11-23 Epix Pharm Inc IDENTIFICATION AND TREATMENT OF INTRAVASCULAR LESIONS
US7504364B2 (en) * 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
DE10231799B4 (de) * 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
US20050037381A1 (en) * 2002-09-16 2005-02-17 Receptors Llc Artificial receptors, building blocks, and methods
WO2005003326A2 (en) * 2003-03-28 2005-01-13 Receptors Llc. Artificial receptors including reversibly immobilized building blocks and methods
US20050136483A1 (en) * 2003-09-03 2005-06-23 Receptors Llc Nanodevices employing combinatorial artificial receptors
US20060057625A1 (en) * 2002-09-16 2006-03-16 Carlson Robert E Scaffold-based artificial receptors and methods
US20040137481A1 (en) * 2002-09-16 2004-07-15 Receptors Llc Artificial receptor building blocks, components, and kits
US20060051802A1 (en) * 2002-09-16 2006-03-09 Receptors Llc Artificial receptors, building blocks, and methods
US20050037429A1 (en) * 2003-03-28 2005-02-17 Receptors Llc Artificial receptors including reversibly immobilized building blocks and methods
US7469076B2 (en) * 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
EP1641495A4 (en) 2003-05-23 2009-02-25 Epix Pharm Inc OPTICALLY PURE AND ENRICHED ISOMERS OF CHEATING LIGANDS AND CONTRASTANTS
DE10325752A1 (de) * 2003-06-06 2004-12-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Lektin-Konjugate
AR047692A1 (es) * 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
US7557577B2 (en) * 2003-12-08 2009-07-07 Siemens Aktiengesselschaft Water-soluble paramagnetic substance reducing the relaxation time of the coolant in an MRI system
WO2005079274A2 (en) * 2004-02-12 2005-09-01 Mount Sinai School Of Medicine Magnetic resonance imaging of atherosclerotic plaque
WO2006028930A2 (en) * 2004-09-03 2006-03-16 Receptors Llc Combinatorial artificial receptors including tether building blocks on scaffolds
WO2006027244A2 (en) * 2004-09-10 2006-03-16 Bracco Imaging S.P.A. Paramagnetic metal polyamino complexes for mri visualization of internalized polynucleotides
US7985715B2 (en) 2004-09-11 2011-07-26 Receptors Llc Combinatorial artificial receptors including peptide building blocks
WO2006056227A1 (en) * 2004-11-27 2006-06-01 Eberhard-Karls- Universität Tübingen Universitätsklinikum Conjugates comprising the active agent and flanking or branched-chain peptides
DE102004062258B3 (de) * 2004-12-23 2006-01-05 Schering Ag Hydroxypyridinon-Derivate, deren Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
EA011516B1 (ru) 2005-01-13 2009-04-28 Синвеншен Аг Композиционный материал и способ его изготовления
US20060275217A1 (en) * 2005-05-06 2006-12-07 Caravan Peter D Chemical exchange saturation transfer contrast agents
WO2007009058A2 (en) * 2005-07-13 2007-01-18 Georgia State University Research Foundation, Inc. Contrast agents and methods for preparing contrast agents
EP1937753A1 (en) * 2005-10-18 2008-07-02 Cinvention Ag Thermoset particles and methods for production thereof
US20070264678A1 (en) 2005-10-28 2007-11-15 Invitrogen Corporation Kinase and ubiquination assays
WO2007084264A2 (en) 2005-12-29 2007-07-26 Epix Pharmaceuticals, Inc. Methods for myocardial imaging
CA2660717A1 (en) * 2006-08-17 2008-02-21 Epix Pharmaceuticals, Inc. Methods for lymph system imaging
US20080280778A1 (en) * 2007-05-03 2008-11-13 Urdea Michael S Binding reagents that contain small epitope binding molecules
DE102007028090A1 (de) 2007-06-12 2008-12-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Aktivierbare diagnostische und therapeutische Verbindung
US8344158B2 (en) * 2007-08-15 2013-01-01 Washington University Fluorescent polymethine cyanine dyes
US20090214436A1 (en) 2008-02-18 2009-08-27 Washington University Dichromic fluorescent compounds
US8765977B2 (en) 2010-03-31 2014-07-01 General Electric Company Hydroxylated contrast enhancement agents and imaging method
US8362281B2 (en) 2010-03-31 2013-01-29 General Electric Company Intermediates for hydroxylated contrast enhancement agents
US8722020B2 (en) 2010-03-31 2014-05-13 General Electric Company Hydroxylated contrast enhancement agents
EP3338617B1 (en) 2012-01-23 2020-08-19 Washington University Goggle imaging systems and devices
US9849201B2 (en) 2013-05-03 2017-12-26 Washington University Homing agents
US10806804B2 (en) 2015-05-06 2020-10-20 Washington University Compounds having RD targeting motifs and methods of use thereof
WO2017004211A1 (en) 2015-06-29 2017-01-05 Collagen Medical, LLC Collagen imaging compositions
JP7523883B2 (ja) 2015-08-13 2024-07-29 ザ ジェネラル ホスピタル コーポレイション 分子ｍｒイメージング用マンガン系キレートコンジュゲート
CA3051253A1 (en) * 2017-02-02 2018-08-09 The University Of Akron Functionalized poly(propylene fumarate) polymers made by ring opening polymerization using magnesium catalysts
US11712482B2 (en) 2019-12-13 2023-08-01 Washington University Near infrared fluorescent dyes, formulations and related methods

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880008A (en) 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4777957A (en) * 1985-06-14 1988-10-18 General Electric Company Method for measuring and imaging fluid flow
JPH07110815B2 (ja) * 1985-11-18 1995-11-29 ボ−ド・オブ・リ−ジェンツ、ザ・ユニバ−シティ−・オブ・テキサス・システム 画像及びスペクトル向上（およびスペクトルシフト）のためのポリキレ−ト剤
ATE89743T1 (de) 1986-08-18 1993-06-15 Dow Chemical Co Conjugate dichter sterne.
US5011686A (en) * 1987-09-21 1991-04-30 Creative Biomolecules, Inc. Thrombus specific conjugates
GB8808305D0 (en) * 1988-04-08 1988-05-11 Nycomed As Compositions
US5914095A (en) 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
GB9320277D0 (en) 1993-10-01 1993-11-17 Nycomed Salutar Inc Chelants
US5650133A (en) 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
ES2116291T3 (es) 1989-10-23 1998-07-16 Nycomed Salutar Inc Agentes quelantes de metales en sitios multiples.
US5631329A (en) 1990-08-27 1997-05-20 Dendritech, Inc. Process for producing hyper-comb-branched polymers
JPH06507904A (ja) * 1991-05-23 1994-09-08 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 磁気共鳴画像形成用の油脂可溶化合物
JP2894879B2 (ja) * 1991-10-04 1999-05-24 日本メジフィジックス株式会社 診断用造影剤
US5522390A (en) * 1991-11-21 1996-06-04 U.S. Philips Corporation Magnetic resonance imaging method
US5637759A (en) 1992-07-30 1997-06-10 The Regents Of The University Of California Metal-ligating amino acid derivatives for MRI and for peptide synthesis
DE69332203T2 (de) 1992-10-02 2003-05-28 Diatide, Inc. Multimerische mehrzweckwirkstoffe gegen thrombose
US5726304A (en) 1992-10-30 1998-03-10 The University Of British Columbia Porphocyanine and CNC-expanded porphyrins
US5401493A (en) * 1993-03-26 1995-03-28 Molecular Biosystems, Inc. Perfluoro-1H,-1H-neopentyl containing contrast agents and method to use same
US5579767A (en) * 1993-06-07 1996-12-03 Prince; Martin R. Method for imaging abdominal aorta and aortic aneurysms
GB9314499D0 (en) * 1993-07-12 1993-08-25 Nycomed Imaging As Method
GB9318550D0 (en) 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants
DE4344460A1 (de) * 1993-12-22 1995-06-29 Schering Ag Metallkomplexe von dendrimeren Makromolekülen, diese enthaltende diagnostische Mittel sowie Verfahren zur Herstellung der Komplexe und Mittel
IT1270994B (it) 1994-03-18 1997-05-26 Bracco Spa Macromolecole ramificate a struttura poliossialchilica e loro usi
WO1995027705A1 (en) * 1994-04-08 1995-10-19 Bracco International B.V. Aromatic amide compounds and metal chelates thereof
GB9407812D0 (en) 1994-04-20 1994-06-15 Nycomed Salutar Inc Compounds
DE4425857A1 (de) 1994-07-07 1996-01-11 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zur ihrer Herstellung und diese enthaltende pharmazeutische Mittel
WO1998053855A1 (en) * 1997-05-30 1998-12-03 Alliance Pharmaceutical Corp. Methods and apparatus for monitoring and quantifying the movement of fluid
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
TW319763B (pt) * 1995-02-01 1997-11-11 Epix Medical Inc
DE19518222A1 (de) 1995-05-11 1996-11-14 Schering Ag Verwendung von polymeren Kontrastmittel mittleren Molekulargewichts zur Differenzierung von benignen und malignen Tumoren mittels moderner bildgebender Verfahren
DE19521945A1 (de) 1995-06-12 1996-12-19 Schering Ag Kaskadenpolymere mit Iodaromaten
DE19525924A1 (de) * 1995-07-04 1997-01-09 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US5919442A (en) 1995-08-11 1999-07-06 Dendritech, Inc. Hyper comb-branched polymer conjugates
IT1277596B1 (it) 1995-09-15 1997-11-11 Bracco Spa Composti macromolecolari di tipo dendrimerico
US6638508B2 (en) * 1995-12-21 2003-10-28 Yeda Research And Development Co., Ltd. Modified avidin-type molecules as targeting agents for the liver and cells of the reticuloendothelial system
IT1283218B1 (it) * 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
CA2247620A1 (en) 1996-04-01 1997-10-09 Epix Medical, Inc. Bioactivated diagnostic imaging contrast agents
WO1997041856A1 (en) * 1996-05-08 1997-11-13 Massachusetts Institute Of Technology ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO)
DE19641197C2 (de) 1996-09-24 1999-02-18 Schering Ag Ionenpaare und ihre Verwendung als Kontrastmittel
US6372194B1 (en) * 1997-03-18 2002-04-16 Toshihiro Akaike MRI contrast media recognizing minor environmental changes
DE19731300C1 (de) 1997-07-11 1999-01-21 Schering Ag Perfluoralkylgruppenhaltige Trijodaromaten, Verfahren zu deren Herstellung und deren Verwendung als Kontrastmittel
US6073042A (en) * 1997-09-25 2000-06-06 Siemens Medical Systems, Inc. Display of three-dimensional MRA images in which arteries can be distinguished from veins
AU752812B2 (en) 1997-11-17 2002-10-03 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
US6858210B1 (en) * 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6112112A (en) * 1998-09-18 2000-08-29 Arch Development Corporation Method and system for the assessment of tumor extent in magnetic resonance images
US6342598B1 (en) * 1998-11-26 2002-01-29 Bracco International B.V. Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
HUP0202635A3 (en) * 1999-07-29 2006-03-28 Epix Medical Inc Cambridge Targeting multimeric imaging agents through multilocus binding
TWI290146B (en) * 1999-07-29 2007-11-21 Dyax Corp Binding moieties for fibrin
WO2002054088A2 (en) * 2001-01-05 2002-07-11 Duke University Contrast enhancement agent for magnetic resonance imaging
US6459264B1 (en) * 2001-02-22 2002-10-01 Mayo Foundation For Medical Education And Research Real-time embedded magnetic resonance fluoroscopy
JP2005534697A (ja) * 2002-08-06 2005-11-17 エピックス ファーマシューティカルズ， インコーポレイテッド ペプチド凝集体

Also Published As

Publication number Publication date
EA200200220A1 (ru) 2002-08-29
WO2001008712A3 (en) 2002-03-14
HUP0202635A3 (en) 2006-03-28
CA2384565A1 (en) 2001-02-08
CN1626246A (zh) 2005-06-15
IL147854A0 (en) 2002-08-14
HUP0202635A2 (hu) 2002-11-28
CZ2002343A3 (cs) 2002-08-14
YU6502A (sh) 2005-06-10
JP2003505519A (ja) 2003-02-12
US20040005274A1 (en) 2004-01-08
MXPA02001017A (es) 2002-08-12
HK1048952A1 (zh) 2003-04-25
WO2001008712A2 (en) 2001-02-08
PL353336A1 (en) 2003-11-17
KR20020057946A (ko) 2002-07-12
EP1210124A2 (en) 2002-06-05
NO20020474D0 (no) 2002-01-29
IS6241A (is) 2002-01-18
NO20020474L (no) 2002-03-27
AU6386000A (en) 2001-02-19
JP2003201258A (ja) 2003-07-18
US6652835B1 (en) 2003-11-25
NZ517017A (en) 2004-05-28
CN1382062A (zh) 2002-11-27

Similar Documents

Publication Publication Date Title
BR0013171A (pt) Agentes multimericos para formação de imagem de objetivação através de ligação multi-local
BRPI0412986A (pt) composto, método para o diagnóstico ou formação de imagem in vivo de uma doença ou condição associadas com a angiogênese, formulação radiofarmacêutica, método para a preparação de um composto, e, kit para a preparação de um peptìdeo radiofluorado
PT907379E (pt) Agentes de contraste bioactivados para imagiologia de diagnostico
Sarda-Mantel et al. Evaluation of 99m Tc-UBI 29-41 scintigraphy for specific detection of experimental Staphylococcus aureus prosthetic joint infections
WO1998018497A3 (en) Contrast agents
DK0836380T3 (da) FGF9 som en specifik ligand for FGFR3
CA2332007A1 (en) Adenosine a3 receptor modulators
KR20180058822A (ko) 전립선 특이적 막 항원（psma)의 18f-태그된 저해제 및 전립선암에 대한 조영제로서 이의 용도
BR0015924A (pt) Compostos triaromáticos análogos de vitamina d, uso de um composto, composição farmacêutica, composição cosmética e uso de uma composição cosmética
BRPI0416938A (pt) agente de formação de imagem, composição, conjugado, kit para a preparação da composição radiofarmacêutica
KR900011717A (ko) 페닐히드라존, 이들의 제조방법 및 이들로부터 제조된 치료 및 미용 조성물
AU4546996A (en) Liposome suspensions as blood pool imaging contrast agents
DK0981363T3 (da) Somatostatinagonister til reduktion af legemsvægt
AU2003276514A1 (en) 4-imidazol-1-ylmethyl-pyrimidine derivatives_as ligands for gabaa receptors
WO2001092476A3 (de) In vitro-gewebetestsystem
WO2008012102A2 (de) Röntgendichtes konjugat
EP4338757A1 (en) New pet tracer for imaging of the functional liver reserve
ATE287733T1 (de) Spinresonanz kontrastmittel für das blut
WO2008157824A3 (en) Thrombopoietin peptide conjugates
WO2004096138A3 (en) [18f]-furanosylpurine derivatives and uses thereof
PL2101826T3 (pl) Znakowane izotopowo związki na bazie peptydów i ich zastosowania
De Costa et al. Iodomorphinans as a Novel Class of Potential Spect Imaging Agents for Opioid Receptors in the CNS
Hutchinson et al. Serum amyloid P component is taken up and catabolised in hepatocytes
Nicolson et al. In vivo and in vitro selection of experimental metastatic variants of rodent melanoma, mammary carcinoma and lymphosarcoma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.